1
EXHIBIT 10.55
COMMON STOCK AND WARRANT PURCHASE AGREEMENT
DATED AS OF OCTOBER 12, 1998
BETWEEN
CELTRIX PHARMACEUTICALS, INC.
AND
THE PURCHASERS LISTED ON EXHIBIT A
2
TABLE OF CONTENTS
Page
----
SECTION 1 - Sale of Common Stock and Warrants.........................................1
1.1 Sale of Common Stock and Warrants.........................................1
1.2 Closing Date..............................................................1
1.3 Delivery..................................................................1
SECTION 2 - Representations and Warranties of Celtrix.................................1
2.1 Organization and Standing.................................................2
2.2 Corporate Power; Authorization............................................2
2.3 Shares; Warrant Shares....................................................2
2.4 Capitalization............................................................3
2.5 SEC Documents; Financial Statements.......................................3
2.6 Governmental Consents.....................................................4
2.7 No Material Adverse Change................................................4
2.8 Intellectual Property.....................................................5
2.9 Litigation................................................................6
2.10 Consistent Terms.........................................................6
2.11 Subsidiaries.............................................................7
2.12 Undisclosed Liabilities..................................................7
2.13 Title to Properties......................................................7
2.14 Employee Matters.........................................................7
2.15 Taxes....................................................................8
2.16 Brokers..................................................................8
2.17 Environmental Matters....................................................8
2.18 Use of Proceeds..........................................................9
2.19 Compliance with Applicable Laws..........................................9
2.20 Disclosure...............................................................9
2.21 Year 2000 Compliance.....................................................9
SECTION 3 - Representations and Warranties of Purchasers.............................10
3.1 Investment Experience....................................................10
3.2 Investment Intent........................................................10
3.3 Registration or Exemption Requirements...................................10
3.4 No Legal, Tax or Investment Advice.......................................10
SECTION 4 - Conditions to Obligations of Purchasers..................................11
4.1 Representations and Warranties Correct...................................11
4.2 Covenants................................................................11
4.3 Opinion of Company's Counsel.............................................11
4.4 No Order Pending.........................................................11
4.5 No Law Prohibiting or Restricting Such Sale..............................11
4.6 Compliance Certificate...................................................11
4.7 No Material Adverse Change...............................................11
4.8 Governmental Approvals...................................................11
4.9 Closing Bid Price of Celtrix Stock.......................................12
i
3
TABLE OF CONTENTS
(CONTINUED)
Page
----
4.10 Deliveries..............................................................12
SECTION 5 - Conditions to Obligations of Celtrix.....................................12
5.1 Representations and Warranties Correct...................................12
5.2 Covenants................................................................12
5.3 No Order Pending.........................................................12
5.4 No Law Prohibiting or Restricting Such Sale..............................12
5.5 Governmental Approvals...................................................13
SECTION 6 - Covenants of Celtrix.....................................................13
6.1 Warrants.................................................................13
6.2 Registration Requirements................................................13
6.3 Financial Information....................................................17
6.4 Budget...................................................................17
6.5 Access...................................................................17
6.6 Board of Directors.......................................................17
6.7 Proceedings..............................................................17
6.8 Insurance................................................................17
6.9 Proprietary Information Agreements.......................................18
6.10 Taxes and Other Liabilities.............................................18
6.11 Corporate Existence.....................................................18
6.12 Business................................................................18
6.13 Compliance with Laws....................................................18
6.14 Indemnification.........................................................18
6.15 Material Events.........................................................20
6.16 Stockholder Ratification................................................20
SECTION 7 - Covenants of Purchasers..................................................20
7.1 Notice to Company of Proposed Sale and Right of Company to Suspend Use
of Registration Statement....................................................20
7.2 Restrictions on Short-Sales..............................................21
SECTION 8 - Restrictions on Transferability of Shares; Compliance With Securities
Act..................................................................................21
8.1 Restrictions on Transferability..........................................21
8.2 Restrictive Legend.......................................................21
SECTION 9 - Miscellaneous............................................................22
9.1 Termination of Agreement.................................................22
9.2 Best Efforts.............................................................22
9.3 Governing Law............................................................22
9.4 Survival.................................................................22
9.5 Successors and Assigns...................................................22
9.6 Entire Agreement; Amendment..............................................22
9.7 Notices and Dates........................................................23
-ii-
4
TABLE OF CONTENTS
(CONTINUED)
Page
----
9.8 Severability.............................................................23
9.9 No Third Party Rights....................................................24
9.10 Counterparts............................................................24
9.11 Expenses................................................................24
Exhibits
A. Schedule of Purchasers
B. Warrant
C. Schedule of Exceptions
D. Budget
-iii-
5
COMMON STOCK AND WARRANT PURCHASE AGREEMENT
THIS COMMON STOCK AND WARRANT PURCHASE AGREEMENT ("Agreement") is
entered into as of this 12th day of October, 1998 (the "Effective Date") between
Celtrix Pharmaceuticals, Inc., a Delaware corporation ("Celtrix"), and the
purchasers listed on the attached Exhibit A (each a "Purchaser" and together the
"Purchasers").
SECTION 1
SALE OF COMMON STOCK AND WARRANTS
1.1 SALE OF COMMON STOCK AND WARRANTS. Subject to the terms and
conditions hereof, Celtrix will issue and sell to each Purchaser, and each
Purchaser will purchase from Celtrix, at the Closing (as defined below) the
number of Units set forth opposite each Purchaser's name on Exhibit A. A "Unit"
shall be composed of one share ("Share") of common stock, $0.01 par value, of
Celtrix ("Common Stock") and a warrant to purchase one and one half shares of
Common Stock (each single share, a "Warrant Share"). A form of the warrant is
attached as Exhibit B ("Warrant"). The purchase price per Unit ("Unit Purchase
Price") shall be $0.50. The exercise price per Warrant Share shall be equal to
110% of the Unit Purchase Price (or $0.55 per Warrant Share). Units shall be
purchased hereunder in even increments.
1.2 CLOSING DATE. The closing of the purchase and sale of the Units
("Closing") shall be held at the law offices of Venture Law Group, 0000 Xxxx
Xxxx Xxxx, Xxxxx Xxxx, Xxxxxxxxxx not later than thirty (30) days after the
Effective Date, or at such other time and place upon which Celtrix and the
Purchasers purchasing a majority of the Units shall mutually agree (the date of
the Closing is hereinafter referred to as the "Closing Date").
1.3 DELIVERY. At the Closing, Celtrix will deliver to each Purchaser
certificates representing the Shares and Warrants purchased by such Purchaser,
against payment of the aggregate Unit Purchase Price therefor, by wire transfer
to Celtrix or certified or cashier's check drawn on a United States bank made to
the order of Celtrix.
SECTION 2
REPRESENTATIONS AND WARRANTIES OF CELTRIX
Celtrix hereby represents and warrants to the Purchasers as of the
Closing Date that, except as set forth on the Schedule of Exceptions attached
hereto as Exhibit C, which exceptions shall be deemed to be representations and
warranties as if made hereunder:
2.1 ORGANIZATION AND STANDING. Celtrix is a corporation duly
organized and validly existing under, and by virtue of, the laws of the State of
Delaware and is in good standing as a domestic corporation under the laws of
said state and is qualified as a foreign corporation in California and in all
other jurisdictions in which such qualification is required; provided, however,
that Celtrix need not be qualified in a jurisdiction in which its failure to
qualify would
6
not have a material adverse effect on the business, properties, prospects or
financial condition of Celtrix.
2.2 CORPORATE POWER; AUTHORIZATION. Celtrix has all requisite legal
and corporate power and has taken all requisite corporate action to execute and
deliver this Agreement and the Warrants, to sell and issue the Shares, the
Warrants and the Warrant Shares and to carry out and perform all of its
obligations under this Agreement and the Warrants. This Agreement and the
Warrants constitute the legal, valid and binding obligation of Celtrix,
enforceable in accordance with their terms, except (i) as limited by applicable
bankruptcy, insolvency, reorganization or similar laws relating to or affecting
the enforcement of creditors' rights generally and (ii) as limited by equitable
principles generally. The execution and delivery of this Agreement and the
Warrants does not, and the performance of this Agreement and the Warrants and
the compliance with the provisions hereof and thereof and the issuance, sale and
delivery of the Shares, the Warrants and the Warrant Shares by Celtrix will not
materially conflict with, or result in a breach or violation of the terms,
conditions or provisions of, or constitute a default under, or result in the
creation or imposition of any lien pursuant to the terms of, the Certificate of
Incorporation or Bylaws of Celtrix or any statute, law, rule or regulation or
any state or federal order, judgment or decree or any note, bond, indenture,
mortgage, lease, license, permit, franchise or other agreement, obligation or
instrument to which Celtrix, or any of its properties, is subject. The execution
and delivery of this Agreement and the Warrant and the consummation of the
transactions contemplated herein and therein have been duly and validly
authorized and approved by Celtrix's Board of Directors, and no other corporate
or stockholder approval or proceedings are necessary to authorize or approve
this Agreement, the Warrant, or to consummate the transactions contemplated
hereby and thereby. True and complete copies of the respective minutes of all
meetings or consent actions of the Board of Directors and stockholders of
Celtrix have been delivered to or made available to Purchasers and accurately
reflect all actions taken by the Board of Directors and stockholders of Celtrix.
As of the date hereof Celtrix is not subject to any bankruptcy or reorganization
proceedings or arrangement or moratorium affecting the enforcement of creditors
rights generally.
2.3 SHARES; WARRANT SHARES. The Shares and the Warrants (and the
Warrant Shares issuable upon exercise of the Warrants) when issued in compliance
with the provisions of this Agreement or the Warrants, as the case may be, will
be duly and validly authorized, issued, fully paid and nonassessable. Based on
the representations and warranties of the Purchasers contained herein, the
Shares and the Warrants (and the Warrant Shares) when issued in compliance with
the provisions of this Agreement or the Warrants, as the case may be, will be
issued in compliance with federal and state securities laws. The issuance and
delivery of the Shares and the Warrants (and the Warrant Shares upon exercise of
the Warrants) is not subject to preemptive or any other similar rights of the
stockholders of Celtrix or any liens or encumbrances. Celtrix has reserved such
number of shares of its Common Stock necessary for issuance of the Warrant
Shares.
2.4 CAPITALIZATION. The authorized capital stock of Celtrix consists
of 60,000,000 shares of Common Stock, $0.01 par value, of which at September 30,
1998, 21,061,053 shares were issued and outstanding, and 10,000,000 shares of
Preferred Stock, $0.01 par value per share, no shares of which are issued and
outstanding. All such issued and outstanding shares
-2-
7
have been duly authorized and validly issued and are fully paid and
nonassessable. All offers and sales of securities by Celtrix have been duly and
properly made pursuant to registrations conducted under applicable federal and
state securities laws or pursuant to exemptions from the registration
requirements thereof. In addition to the foregoing, Celtrix has reserved and
outstanding the following warrants, options and convertible securities: (i)
warrants for the purchase of 687,155 shares of Common Stock at an exercise price
of $9.00 per share, which warrants expire November 17, 1998; (ii) warrants for
the purchase of 2,860,934 shares of Common Stock at an exercise price of $2.6818
per share, which warrants expire April 1, 2000; (iii) an option for the purchase
of 75,000 shares of Common Stock at an exercise price of $2.438 per share, which
option expires April 1, 2000; (iv) 3,000,000 shares reserved for issuance
pursuant to Celtrix's 1991 Stock Option Plan, of which, at September 30, 1998
options to purchase 32,174 shares had been exercised, options to purchase
1,714,358 shares were outstanding and 1,253,468 shares remained available for
future grant; (v) 500,000 shares reserved for issuance pursuant to Celtrix's
1991 Employee Stock Purchase Plan, of which, at September 30, 1998, 176,880
shares had been issued and 323,120 shares remained available for future
issuance; and (vi) 200,000 shares reserved for issuance under Celtrix's 1991
Directors' Stock Option Plan, of which, at September 30, 1998, options to
purchase 29,999 shares were outstanding and 170,001 shares remained available
for future grant. Except for securities issued in the ordinary course of
business under Celtrix's stock plans, no additional securities of Celtrix will
be issued and outstanding as of the Closing. Except as described in this Section
2.4 and except for X.X. Xxxxxxx, Xxxxxx and Company's right to purchase such
amount of newly issued securities of Celtrix in order to maintain their
respective percentage ownership of Celtrix Common Stock (which rights have been
waived by X.X. Xxxxxxx, Xxxxxx and Company in connection with the transactions
contemplated by this Agreement), there are no other options, warrants,
conversion privileges or other contractual rights currently outstanding that
would obligate Celtrix to sell or otherwise issue any authorized but unissued
shares of Celtrix's capital stock or other securities or to grant or enter into
any such option, warrant, conversion privilege or other contractual right to
purchase or otherwise acquire Celtrix securities. In addition to the foregoing,
as of the date hereof, Celtrix has no bonds, debentures, notes or other
indebtedness outstanding that have voting rights in Celtrix, and Celtrix is not
subject to any agreement, understanding or commitment which would require it to
issue any such bonds, debentures, notes or other indebtedness. Except as set
forth in the Schedule of Exceptions, Celtrix is not presently under any
contractual obligation to register any of its presently outstanding securities
or any of its securities that may be hereafter issued.
2.5 SEC DOCUMENTS; FINANCIAL STATEMENTS. Each complete or partial
statement, report, prospectus and other document filed by Celtrix under the
Securities Act of 1933, as amended ("Securities Act") and the Securities
Exchange Act of 1934, as amended ("Exchange Act"), is a true and complete copy
of or excerpt from such document as filed by Celtrix with the SEC ("SEC
Documents"). Celtrix has filed all the documents that Celtrix was required to
file with the SEC under Sections 13 or 14(a) of the Exchange Act since the date
on which its Registration Statement filed in connection with its initial public
offering of securities was declared effective. As of their respective filing
dates, the SEC Documents complied in all material respects with the requirements
of the Exchange Act or the Securities Act, as applicable. None of the SEC
Documents as of their respective dates contained any untrue statement of a
-3-
8
material fact or omitted to state a material fact required to be stated therein
or necessary to make the statements made therein, in light of the circumstances
under which they were made, not misleading. The financial statements of Celtrix
included in the SEC Documents ("Financial Statements") comply as to form in all
material respects with applicable accounting requirements and with the published
rules and regulations of the SEC with respect thereto. Except as may be
indicated in the notes to the Financial Statements or, in the case of unaudited
statements, as permitted by Form 10-Q of the SEC, the Financial Statements have
been prepared in accordance with generally accepted accounting principles
consistently applied and fairly present the consolidated financial position of
Celtrix and any subsidiaries at the dates thereof and the consolidated results
of their operations and consolidated cash flows for the periods then ended
(subject, in the case of unaudited statements, to normal, recurring
adjustments). To the knowledge of Celtrix, no holder of any securities of
Celtrix has any bona fide claim against Celtrix pursuant to any federal or state
law, including, but not limited to Section 10(b)(5) of the Exchange Act.
2.6 GOVERNMENTAL CONSENTS. No consent, approval, order or
authorization of, or registration, qualification, designation, declaration or
filing with, any federal, state, or local governmental authority, including
without limitation the U.S. Food and Drug Administration, on the part of Celtrix
is required in connection with the consummation of the transactions contemplated
by this Agreement except for (a) compliance with foreign securities laws,
federal securities laws and state "blue sky" laws in the jurisdictions in which
Units are offered and/or sold, which compliance will be effected in accordance
with such laws, (b) filing the Nasdaq National Market Notification Form for
listing of additional shares, which filing will be effected in accordance with
the rules thereunder or an appropriate waiver will be obtained, and (c) filing
with the SEC and NASD either a Current Report on Form 8-K or a Quarterly or
Annual Report on Form 10-Q or 10-K disclosing the terms of the transaction
contemplated by this Agreement. The business of Celtrix is not being conducted
in violation of any law, ordinance or regulation of any governmental entity,
including but not limited to the U.S. Food and Drug Administration, except for
violations which either singly or in the aggregate would not be reasonably
likely to have a material adverse effect on Celtrix's business, financial
condition or results of operations.
2.7 NO MATERIAL ADVERSE CHANGE. Except as otherwise disclosed herein
or in the Financial Statements, since June 30, 1998, there has not been:
(a) any changes in the assets, liabilities, financial condition
or operations of Celtrix from that reflected in the Financial Statements except
changes in the ordinary course of business which have not been, either in any
individual case or in the aggregate, materially adverse;
(b) any material change in the contingent obligations of Celtrix,
whether by way of guarantee, endorsement, indemnity, warranty or otherwise;
(c) any damage, destruction or loss, whether or not covered by
insurance, materially and adversely affecting the properties or business of
Celtrix;
-4-
9
(d) any declaration or payment of any dividend or other
distribution of the assets of Celtrix;
(e) any labor organization activity;
(f) any purchase or redemption of the capital stock of Celtrix;
(g) any declaration, payment, or commitment for the payment by
Celtrix of a bonus or other additional salary, compensation or benefit to any
employee of Celtrix that was not in the ordinary course of business;
(h) any release, compromise, waiver or cancellation of any debts
to or claims by Celtrix, or waiver of any rights of Celtrix;
(i) any capital expenditure in excess of $10,000 for a single
item or $25,000 in the aggregate;
(j) any change in accounting methods or practices or revaluation
of assets of Celtrix;
(k) any loans by Celtrix or guarantees by Celtrix of any loans;
(l) any termination of any material contract, or any amendment of
a material contract to which Celtrix is a party;
(m) any resignation by or termination of key employees of
Celtrix;
(n) any failure by Celtrix to satisfy any debts, obligations or
liabilities as the same come due; or
(o) any agreement or commitment to any of the foregoing, or any
other event or condition of any character which has materially and adversely
affected Celtrix's assets, liabilities, financial condition or operations or
prospects.
2.8 INTELLECTUAL PROPERTY. Celtrix has sufficient title and ownership
of all patents, patent applications, copyrights, trade secrets, trademarks,
proprietary information, proprietary rights, and processes necessary for its
business as now conducted and as now proposed to be conducted without any
conflict with or infringement of the rights of others except as disclosed in the
documents filed with the SEC, to the knowledge of Celtrix. The research,
development, manufacture, sale, and use of products presently made, used, or
sold by, or contemplated for future manufacture, sale or use by Celtrix, do not
and would not constitute or involve a significant risk of infringement of any
patent or misappropriation of any trade secret of any third party, except as
disclosed in the SEC Documents. Except as disclosed in the documents filed with
the SEC, there are no outstanding options, licenses, or agreements of any kind
relating to any material use of the foregoing, nor is Celtrix bound by or a
party to any options, licenses, encumbrances or liens, or any outstanding
orders, judgments, decrees, stipulations, or agreements of any kind with respect
to the patents, trademarks, service marks, trade names, copyrights, trade
-5-
10
secrets, licenses, information, proprietary rights and processes of any other
person or entity that are material to Celtrix's business as currently conducted
or as now proposed to be conducted. Except as disclosed in the documents filed
with the SEC, Celtrix has not received any communications alleging, nor does
Celtrix have any reason to believe, that Celtrix, by conducting its business as
proposed, would violate any of the patents, trademarks, service marks, trade
names, copyrights, or trade secrets or other proprietary rights of any other
person or entity. Celtrix is not aware that any of its employees or consultants
is obligated under any contract (including licenses, covenants or commitments of
any nature) or other agreement, or subject to any judgment, decree or order of
any court or administrative agency, that is violated by or would materially
interfere with the current or prospective services provided to Celtrix by the
employee or consultant or the use of his best efforts to promote the interests
of Celtrix or that would materially conflict with Celtrix's business as now
proposed to be conducted. Neither the execution nor delivery of this Agreement,
nor the carrying on of Celtrix's business as proposed, will, to Celtrix's
knowledge, conflict with or result in a material breach of the terms, conditions
or provisions of, or constitute a material default under, any contract, covenant
or instrument under which any of such employees is now obligated. To Celtrix's
knowledge, no third party is conducting or planning to conduct any activity that
would constitute an infringement of Celtrix's intellectual property rights.
2.9 LITIGATION. Celtrix is not engaged in, or a party to, or
threatened with, any claim or legal action or other proceeding before any court,
any arbitrator of any kind or any administrative agency, or any governmental
investigation, which could have a material adverse effect on Celtrix's business,
financial condition or results of operations, nor to Celtrix's knowledge does
any basis for any claim or legal action or other proceeding or governmental
investigation exist. There are no orders, rulings, decrees, judgments or
stipulations to which Celtrix is a party by or with any court, arbitrator or
administrative agency and to Celtrix's knowledge, there are no other such
orders, rulings, decrees, judgments or stipulations affecting Celtrix's
business, financial condition or results of operations.
2.10 CONSISTENT TERMS. No Units are being issued and sold at the
Closing other than pursuant to the Agreement and if Celtrix shall enter into any
other agreement, side letter or other understanding with any Purchaser listed on
Exhibit A or any other purchaser containing additional or contrary undertakings
or terms to those contained herein in connection with the issuance and sale of
Units at the Closing, Celtrix shall make such undertakings or terms available to
each other Purchaser.
2.11 SUBSIDIARIES. Celtrix has no subsidiaries and does not otherwise
own or control, directly or indirectly, any equity interest in, or any security
convertible into an equity interest in, any corporation, partnership, limited
liability company, joint venture, association or other business entity.
2.12 UNDISCLOSED LIABILITIES. Celtrix does not have any debt,
liability or obligation of any kind, whether accrued, absolute or otherwise,
including, without limitation, any liability or obligation on account of taxes
or any governmental charges or penalty, interest or fines, except
-6-
11
liabilities reflected on the Financial Statements and liabilities incurred as a
result of the transactions contemplated by this Agreement, including the costs
associated with this transaction.
2.13 TITLE TO PROPERTIES. Celtrix has good and marketable title to all
tangible property and assets set forth in its June 30, 1998 balance sheet and
good title to all of its leasehold interests, in each case, free and clear of
any and all liens, claims and encumbrances.
2.14 EMPLOYEE MATTERS.
(a) Celtrix is not a party to any collective bargaining
agreement, no collective bargaining agent has been certified as a representative
of any of the employees of Celtrix, no representation campaign or election is
now in progress with respect to any employee of Celtrix and there are no labor
disputes, grievances, controversies, strikes or requests for union
representation pending, or, to the knowledge of Celtrix, threatened, relating to
or affecting the Business. To the knowledge of Celtrix, no event has occurred
that could give rise to any such dispute, controversy, strike or request for
representation.
(b) Except as disclosed in the SEC Documents, there are no
employee benefit plans, agreements or arrangements maintained by Celtrix,
including, without limitation, (i) "employee benefit plans," within the meaning
of Section 3(3) of the Employee Retirement Income Security Act of 1974, as
amended ("ERISA"); (ii) affirmative action plans; (iii) current or deferred
compensation, pension, profit sharing, vacation or severance plans or programs;
or (iv) medical, hospital, accident, disability or death benefit plans
(collectively, "Benefit Plans"). All the Benefit Plans are administered in
accordance with, and are in material compliance with, all applicable laws and
regulations. No default exists with respect to the obligations of Celtrix under
any Benefit Plans.
(c) All the Benefit Plans that are subject to ERISA have been
administered in accordance with, and are in compliance with, the applicable
provisions of ERISA. Each of Celtrix's Benefit Plans that is intended to meet
the requirements of Section 401(a) of the Internal Revenue Code of 1986, as
amended (the "Code") has been determined by the Internal Revenue Service to meet
such requirements within the meaning of such provision. No Celtrix Benefit Plan
is subject to Title IV of ERISA or Section 412 of the Code. Celtrix has not
engaged in any nonexempt "prohibited transactions," as such term is defined in
Section 4975 of the Code or Section 406 of ERISA, involving Celtrix Benefit
Plans that would subject Celtrix to the penalty or tax imposed under Section
502(i) of ERISA or Section 4975 of the Code. Celtrix has not engaged in any
transaction described in Section 4069 of ERISA within the last five years.
Neither the execution and delivery of this Agreement nor the consummation of the
transactions contemplated hereby will (i) result in any payment (including,
without limitation, severance, unemployment compensation or golden parachute)
becoming due to any director or other employee of Celtrix, (ii) increase any
benefits otherwise payable under any Benefit Plan or (iii) result in the
acceleration of the time of payment or vesting of any such benefits to any
extent.
(d) No notice of a "reportable event," within the meaning of
Section 4043 of ERISA for which the 30-day reporting requirement has not been
waived, has been required to be
-7-
12
filed for any Benefit Plan that is an "employee pension benefit plan" within the
meaning of Section 3(2) of ERISA and that is intended to meet the requirements
of Section 401(a) of the Code, or by any entity that is considered one employer
with Celtrix under Section 4001 of ERISA or Section 414 of the Code (an "ERISA
Affiliate"), within the 12-month period ending on the date hereof. Celtrix has
not incurred any liability to the Pension Benefit Guaranty Corporation in
respect of any Benefit Plan that remains unpaid.
2.15 TAXES.
(a) As of the date hereof, Celtrix has filed all federal, state
and local tax returns required to be filed by it, all of such returns were
correct and complete as of the time of filing, and Celtrix has paid all taxes
required to be paid by it. Celtrix has provided or made available to Purchasers
copies of all federal, state and local income, franchise, excise, real and
personal property and other tax returns and reports, including extensions, filed
by Celtrix on or prior to the date hereof. As of the date hereof, Celtrix has
not been subject to any tax audit.
(b) Celtrix is not a party to, or bound by, or otherwise in any
way obligated under, any tax sharing or similar agreement.
2.16 BROKERS. Except for the agreement with BioAsia dated _______,
1998, no broker or finder is entitled to any broker's or finder's fee or other
commission in connection with the transactions contemplated by this Agreement as
a result of arrangements made by or on behalf of Celtrix.
2.17 ENVIRONMENTAL MATTERS.
(a) To the knowledge of Celtrix, no real property currently or
formerly owned or operated by Celtrix is contaminated with any Hazardous
Substances (as hereinafter defined).
(b) Celtrix is not a party to any litigation or administrative
proceeding nor, to the knowledge of Celtrix, is any litigation or administrative
proceeding threatened against it, that, in either case, asserts or alleges that
Celtrix (i) violated any Environmental Laws (as hereinafter defined); (ii) is
required to clean up, remove or take remedial or other response action due to
the disposal, deposit, discharge, leak or other release of any Hazardous
Substances; or (iii) is required to pay all or a portion of the cost of any
past, present or future cleanup, removal or remedial or other action that arises
out of or is related to the disposal, deposit, discharge, leak or other release
of any Hazardous Substances.
(c) To the knowledge of Celtrix, there are not now nor have there
previously been tanks or other facilities on, under, or at any real property
owned, leased, used or occupied by Celtrix containing materials that, if known
to be present in soils or ground water, would require cleanup, removal or other
remedial action under Environmental Laws.
(d) To the knowledge of Celtrix, Celtrix is not subject to any
judgment, order or citation related to or arising out of any Environmental Laws
and has not been named or listed
-8-
13
as a potentially responsible party by any governmental agency in a matter
related to or arising out of any Environmental Laws.
(e) For purposes of this Agreement, (i) the term "Environmental
Law" means any federal, state or local law (including statutes, regulations,
ordinances, codes, rules, judicial opinions and other governmental restrictions
and requirements), relating to the discharge of air pollutants, water
pollutants, noise, odors or process waste water, or otherwise relating to the
environment or hazardous or toxic substances; and (ii) the term "Hazardous
Substance" means any toxic or hazardous substance that is regulated by or under
authority of any Environmental Law, including, without limitation, any petroleum
products, asbestos or polychlorinated biphenyls.
2.18 USE OF PROCEEDS. The proceeds of the transactions contemplated by
this Agreement will be used in accordance with Schedule 2.18 hereto.
2.19 COMPLIANCE WITH APPLICABLE LAWS. Celtrix holds all material
permits, licenses, variances, exemptions, orders and approvals necessary to own,
lease or operate all of the assets and properties of Celtrix, as appropriate,
and to carry on its business as now conducted and contemplated (the "Permits").
Celtrix is in material compliance with all applicable laws, ordinances and
regulations and the terms of the Permits.
2.20 DISCLOSURE. To Celtrix's knowledge, it has disclosed to Purchasers
all material information regarding Celtrix requested by Purchasers.
2.21 YEAR 2000 COMPLIANCE. All software utilized by Celtrix in its
business and all equipment and all systems utilized by Celtrix having embedded
microchips will properly execute across and within multiple century dates so
that when the years 2000 and beyond are introduced, such software and systems
will neither fail nor produce incorrect results relating to date or any other
processing. Celtrix has undertaken efforts to confirm that all third parties
with whom it has material relationships, including but not limited to vendors
and customers, will not have material disruptions in their software or systems
related to the year 2000.
SECTION 3
REPRESENTATIONS AND WARRANTIES OF PURCHASERS
Each Purchaser hereby separately represents and warrants, severally and
not jointly, to Celtrix as of the Closing date as follows:
3.1 INVESTMENT EXPERIENCE. Such Purchaser is an "accredited investor"
as defined in Rule 501(a) under the Securities Act. Purchaser is aware of
Celtrix's business affairs and financial condition and has had access to and has
acquired sufficient information about Celtrix to reach an informed and
knowledgeable decision to acquire the Units (and the Warrant Shares issuable
upon exercise of the Warrants). Purchaser has such business and financial
experience as is required to give it the capacity to protect its own interests
in connection with the purchase of the Units.
-9-
14
3.2 INVESTMENT INTENT. Purchaser is purchasing the Units (and the
Warrant Shares upon exercise of the Warrants) for investment for its own account
only and not with a view to, or for resale in connection with, any
"distribution" thereof within the meaning of the Securities Act. Purchaser
understands that the Shares, the Warrants and the Warrant Shares have not been
registered under the Securities Act or registered or qualified under any state
securities law in reliance on specific exemptions therefrom, which exemptions
may depend upon, among other things, the bona fide nature of Purchaser's
investment intent as expressed herein.
3.3 REGISTRATION OR EXEMPTION REQUIREMENTS. Purchaser further
acknowledges and understands that the Shares, the Warrants and the Warrant
Shares must be held indefinitely unless they are subsequently registered under
the Securities Act or an exemption from such registration is available.
Purchaser understands that the certificate(s) evidencing the Shares will be
imprinted with a legend that prohibits the transfer of the Shares unless (i)
they are registered or such registration is not required, and (ii) if the
transfer is pursuant to an exemption from registration other than Rule 144 under
the Securities Act, and, if Celtrix shall so request in writing, an opinion of
counsel satisfactory to Celtrix is obtained to the effect that the transaction
is so exempt. In addition, Purchaser will refrain from selling, transferring or
otherwise disposing of any Shares, the Warrants or the Warrant Shares, or any
interest therein, unless the same are registered under the Securities Act or
applicable state securities or blue sky laws, or an exemption therefrom is
applicable.
3.4 NO LEGAL, TAX OR INVESTMENT ADVICE. Purchaser understands that
nothing in this Agreement or any other materials presented to Purchaser in
connection with the purchase and sale of the Units (and the Warrant Shares
issuable upon exercise of the Warrants) constitutes legal, tax or investment
advice. Purchaser has consulted such legal, tax and investment advisors as it,
in its sole discretion, has deemed necessary or appropriate in connection with
its purchase of the Units (and the Warrant Shares issuable upon exercise of the
Warrants).
SECTION 4
CONDITIONS TO OBLIGATIONS OF PURCHASERS
Each Purchaser's obligation to purchase the Units at the Closing is
subject to the fulfillment on or prior to the Closing Date of the following
conditions, unless otherwise waived by such Purchaser:
4.1 REPRESENTATIONS AND WARRANTIES CORRECT. The representations and
warranties made by Celtrix in Section 2 hereof shall be true and correct when
made, and shall be true and correct on the Closing Date with the same force and
effect as if they had been made on and as of said date.
4.2 COVENANTS. All covenants, agreements and conditions contained in
this Agreement to be performed by Celtrix on or prior to the Closing Date shall
have been performed or complied with in all material respects.
-10-
15
4.3 OPINION OF COMPANY'S COUNSEL. Purchaser shall have received from
Venture Law Group, counsel to Celtrix, an opinion addressed to it, dated the
Closing Date, in form and substance satisfactory to Purchaser.
4.4 NO ORDER PENDING. There shall not then be in effect any order
enjoining or restraining the transactions contemplated by this Agreement.
4.5 NO LAW PROHIBITING OR RESTRICTING SUCH SALE. There shall not be
in effect any law, rule or regulation prohibiting or restricting such sale, or
requiring any consent or approval of any person which shall not have been
obtained to issue the Units (except as otherwise provided in this Agreement).
4.6 COMPLIANCE CERTIFICATE. Celtrix shall have delivered to
Purchasers a certificate executed on behalf of Celtrix by a duly authorized
officer of Celtrix, dated the Closing Date, and certifying to the fulfillment of
the conditions specified in Sections 4.1 and 4.2. Notwithstanding the preceding
sentence, Celtrix shall not be required to deliver such a certificate if the
Closing Date and the execution date of this Agreement are the same.
4.7 NO MATERIAL ADVERSE CHANGE. There shall have been no material
adverse change between the date of this Agreement and the Closing Date in the
financial condition, business or affairs of Celtrix.
4.8 GOVERNMENTAL APPROVALS. All consents from governmental agencies
required to consummate the transaction contemplated hereby shall have been
obtained.
4.9 CLOSING BID PRICE OF CELTRIX COMMON STOCK. The closing bid price
of Celtrix Common Stock as reported on the Nasdaq National Market on the trading
day preceding the Closing Date shall not be less than $0.4375 per share. Any
Purchaser who elects not to proceed with the transaction due to such condition
not being complied with will have no further obligation or liability to Celtrix
arising from or related to this Agreement.
4.10 DELIVERIES. Purchasers shall receive from Celtrix (i)
certificates of Good Standing for Celtrix issued by the Secretaries of State of
the States of Delaware, California, and all other jurisdictions in which Celtrix
is required to be authorized to conduct business as a foreign corporation; (ii)
a copy of the resolutions of the Board of Directors of Celtrix authorizing the
execution, delivery and performance of this Agreement, the Warrant and the
transactions contemplated hereby and thereby certified by the Secretary of
Celtrix as being true and correct copies of such resolutions and in full force
and effect as of the date of the Closing; (iii) stock certificates evidencing
the shares of Celtrix Common Stock purchased hereunder and (iv) the Warrant.
-11-
16
SECTION 5
CONDITIONS TO OBLIGATIONS OF CELTRIX
Celtrix's obligation to sell and issue the Units at the Closing is
subject to the fulfillment on or prior to the Closing Date of the following
conditions by each of the Purchasers, unless otherwise waived by Celtrix:
5.1 REPRESENTATIONS AND WARRANTIES CORRECT. The representations and
warranties made by each Purchaser in Section 3 hereof shall be true and correct
in all material respects when made, and shall be true and correct in all
material respects on the Closing Date with the same force and effect as if they
had been made on and as of said date.
5.2 COVENANTS. All covenants, agreements and conditions contained in
this Agreement to be performed by each Purchaser on or prior to the Closing Date
shall have been performed or complied with in all material respects.
5.3 NO ORDER PENDING. There shall not then be in effect any order
enjoining or restraining the transactions contemplated by this Agreement.
5.4 NO LAW PROHIBITING OR RESTRICTING SUCH SALE. There shall not be in
effect any law, rule or regulation prohibiting or restricting such sale, or
requiring any consent or approval of any person which shall not have been
obtained to issue the Units (except as otherwise provided in this Agreement).
5.5 GOVERNMENTAL APPROVALS. All consents from governmental agencies
required to consummate the transaction contemplated hereby shall have been
obtained.
SECTION 6
COVENANTS OF CELTRIX
Until the termination of this Agreement in accordance with Section 9.1
hereof or the particular covenant, as the case may be:
6.1 WARRANTS. Celtrix will comply with the provisions of the Warrants
contained in the Form of Warrant attached as Exhibit B hereto.
6.2 REGISTRATION REQUIREMENTS.
(a) As soon as reasonably practicable and in any event no later
than 30 days after the Closing, Celtrix shall prepare and file a registration
statement ("Registration Statement") with the SEC under the Securities Act to
register the resale of the Shares and the Warrant Shares ( "Registrable
Securities") and thereafter shall use its best efforts to secure the
effectiveness of such registration statement, such effectiveness to be declared
no later than 90 days after the Closing. In the event that Celtrix fails to file
the Registration Statement with the SEC within 30 days after the Closing or the
SEC does not declare the Registration Statement
-12-
17
effective within 90 days after the Closing, then Celtrix will pay to the
Purchasers by wire transfer or certified check or cashier's check sent to the
Purchasers' designated account or representative, as the case may be, an amount
equal to 2% of the aggregate Purchase Price hereunder for each month that the
effectiveness of the Registration Statement is delayed. Such amount, however,
shall be pro-rated for any month in which the Registration Statement is declared
effective.
(b) Celtrix shall pay all Registration Expenses (as defined
below) in connection with any registration, qualification or compliance
hereunder, and each holder of Registrable Securities ("Holder") shall pay all
Selling Expenses (as defined below) and other expenses that are not Registration
Expenses relating to the Registrable Securities resold by such Holder.
"Registration Expenses" shall mean all expenses, except for Selling Expenses,
incurred by Celtrix in complying with the registration provisions herein
described, including, without limitation, all registration, qualification and
filing fees, printing expenses, escrow fees, fees and disbursements of counsel
for Celtrix, blue sky fees and expenses and the expense of any special audits
incident to or required by any such registration. "Selling Expenses" shall mean
all selling commissions, underwriting fees and stock transfer taxes applicable
to the Registrable Securities and all fees and disbursements of counsel for any
Holder.
(c) In the case of any registration effected by Celtrix pursuant
to these registration provisions, Celtrix will use its best efforts to: (i) keep
such registration effective until the earlier of (A) two (2) years after the
Closing Date or (B) such date as Celtrix shall be satisfied that the
then-current Holders may sell all of their Registrable Securities then
outstanding within a three (3) month period; (ii) prepare and file with the SEC
such amendments and supplements to such Registration Statement and the
prospectus used in connection with such Registration Statement as may be
necessary to comply with the provisions of the Securities Act with respect to
the disposition of all securities covered by such Registration Statement; (iii)
furnish such number of prospectuses and other documents incident thereto,
including any amendment of or supplement to the prospectus, as a Holder from
time to time may reasonably request; (iv) use its best efforts to register and
qualify the securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably
requested by the Holders, provided that Celtrix shall not be required in
connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such states or
jurisdictions; (v) cause all such Registrable Securities registered as described
herein to be listed on each securities exchange and quoted on each quotation
service on which similar securities issued by Celtrix are then listed or quoted;
(vi) provide a transfer agent and registrar for all Registrable Securities
registered pursuant to such Registration Statement and a CUSIP number for all
Registrable Securities; and (vii) otherwise use its best efforts to comply with
all applicable rules and regulations of the SEC, and make available to its
security holders, as soon as reasonably practicable, an earnings statement
covering the period of at least twelve months, but not more than eighteen
months, beginning with the first month after the effective date of the
registration statement, which earnings statement shall satisfy the provisions of
Section 11(a) of the Securities Act.
(d) When a Holder is entitled to sell and gives notice of its
intent to sell pursuant to the Registration Statement, Celtrix shall, within
three (3) trading days (subject to
-13-
18
Section 7.1), furnish to such Holder a reasonable number of copies of a
supplement to or an amendment of such prospectus as may be necessary so that, as
thereafter delivered to the Holders of such shares, such prospectus shall not
include an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein not
misleading or incomplete in the light of the circumstances then existing.
(e) The right to sell Registrable Securities pursuant to the
Registration Statement described herein will automatically be assigned to each
transferee of Registrable Securities. In the event that it is necessary, in
order to permit a Holder to sell Registrable Securities pursuant to Celtrix's
Registration Statement, to amend the Registration Statement to name such Holder,
such Holder shall, upon written notice to Celtrix, be entitled to have Celtrix
make such amendment as soon as reasonably practicable. Notwithstanding the above
provisions relating to Registration Expenses, in the event that such an
amendment is requested, the Holder shall, at the request of Celtrix, be
obligated to reimburse Celtrix for reasonable Registration Expenses incurred by
it in connection with such amendment.
(f) With a view to making available to the holders the benefits
of Rule 144 promulgated under the Securities Act and any other rule or
regulation of the SEC that may at any time permit a Holder to sell Registrable
Securities to the public without registration or pursuant to a registration on
Form S-3, Celtrix hereby covenants and agrees to: (i) make and keep public
information available, as those terms are understood and defined in Rule 144, at
all times after the closing; (ii) file with the SEC in a timely manner all
reports and other documents required of Celtrix under the Securities Act and
Exchange Act; and (iii) furnish to any Holder, as long as the Holder owns any
Registrable Securities forthwith upon request, (A) a written statement by
Celtrix that it has complied with the reporting requirements of Rule 144, the
Securities Act and the Exchange Act, (B) a copy of the most recent annual or
quarterly report of Celtrix, and (C) such other information as may be reasonably
requested in order to avail any Holder of any rule or regulation of the SEC that
permits the selling of any such Registrable Securities without registration or
pursuant to such Form S-3.
(g) INDEMNIFICATION.
(i) To the extent permitted by law, Celtrix will
indemnify and hold harmless each Holder, any underwriter (as defined in the Act)
for such Holder, its officers, directors, shareholders or partners and each
person, if any, who controls such Holder or underwriter within the meaning of
the Act or the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
against any losses, claims, damages, or liabilities (joint or several) to which
they may become subject under the Act, the Exchange Act or other federal or
state law, insofar as such losses, claims, damages, or liabilities (or actions
in respect thereof) arise out of or are based upon any of the following
statements, omissions or violations (collectively a "Violation"): (A) any untrue
statement or alleged untrue statement of a material fact contained in such
Registration Statement, including any preliminary prospectus or final prospectus
contained therein or any amendments or supplements thereto, (B) the omission or
alleged omission to state therein a material fact required to be stated therein,
or necessary to make the statements therein not misleading, or (C) any violation
or alleged violation by Celtrix of the Act, the Exchange Act,
-14-
19
any state securities law or any rule or regulation promulgated under the Act,
the Exchange Act or any state securities law; and Celtrix will pay to each such
Holder, underwriter or controlling person, as incurred, any legal or other
expenses reasonably incurred by them in connection with investigating or
defending any such loss, claim, damage, liability, or action; provided, however,
that the indemnity agreement contained in this Section 6.2(g)(i) shall not apply
to amounts paid in settlement of any such loss, claim, damage, liability, or
action if such settlement is effected without the consent of Celtrix (which
consent shall not be unreasonably withheld), nor shall Celtrix be liable in any
such case for any such loss, claim, damage, liability, or action to the extent
that it arises out of or is based upon a Violation which occurs in reliance upon
and in conformity with written information furnished expressly for use in
connection with such registration by any such Holder, underwriter or controlling
person.
(ii) To the extent permitted by law, each selling Holder
will indemnify and hold harmless Celtrix, each of its directors, each of its
officers who has signed the Registration Statement, each person, if any, who
controls Celtrix within the meaning of the Act, any underwriter, any other
Holder selling securities in such Registration Statement and any controlling
person of any such underwriter or other Holder, against any losses, claims,
damages, or liabilities (joint or several) to which any of the foregoing persons
may become subject, under the Act, the Exchange Act or other federal or state
law, insofar as such losses, claims, damages, or liabilities (or actions in
respect thereto) arise out of or are based upon any Violation, in each case to
the extent (and only to the extent) that such Violation occurs in reliance upon
and in conformity with written information furnished by such Holder expressly
for use in connection with such registration; and each such Holder will pay, as
incurred, any legal or other expenses reasonably incurred by any person intended
to be indemnified pursuant to this subsection 6.2(g)(ii), in connection with
investigating or defending any such loss, claim, damage, liability, or action;
provided, however, that the indemnity agreement contained in this subsection
6.2(g)(ii) shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability or action if such settlement is effected without the
consent of the Holder, which consent shall not be unreasonably withheld;
provided, that, in no event shall any indemnity under this subsection 6.2(g)(ii)
exceed the net proceeds from the offering received by such Holder, except in the
case of willful fraud by such Holder.
(iii) Promptly after receipt by an indemnified party under
this Section 6.2(g) of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 6.2(g), deliver
to the indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties which may be represented without
conflict by one counsel) shall have the right to retain one separate counsel,
with the reasonable fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by such
counsel in such proceeding. The failure to deliver
-15-
20
written notice to the indemnifying party within a reasonable time of the
commencement of any such action, if prejudicial to its ability to defend such
action, shall relieve such indemnifying party of any liability to the
indemnified party under this Section 6.2(g), but the omission so to deliver
written notice to the indemnifying party will not relieve it of any liability
that it may have to any indemnified party otherwise than under this Section
6.2(g).
(iv) If the indemnification provided for in this Section
6.2(g) is held by a court of competent jurisdiction to be unavailable to an
indemnified party with respect to any loss, liability, claim, damage, or expense
referred to therein, then the indemnifying party, in lieu of indemnifying such
indemnified party hereunder, shall contribute to the amount paid or payable by
such indemnified party as a result of such loss, liability, claim, damage, or
expense in such proportion as is appropriate to reflect the relative fault of
the indemnifying party on the one hand and of the indemnified party on the other
in connection with the statements or omissions that resulted in such loss,
liability, claim, damage, or expense as well as any other relevant equitable
considerations; provided, that, in no event shall any contribution by a Holder
under this subsection 6.2(g)(iv) exceed the net proceeds from the offering
received by such Holder, except in the case of willful fraud by such Holder. The
relative fault of the indemnifying party and of the indemnified party shall be
determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or the omission to state a material fact
relates to information supplied by the indemnifying party or by the indemnified
party and the parties' relative intent, knowledge, access to information, and
opportunity to correct or prevent such statement or omission.
(v) The obligations of Celtrix and Holders under this
Section 6.2(g) shall survive the completion of any offering of Registrable
Securities in a Registration Statement under this Section 6.2(g), and otherwise.
6.3 FINANCIAL INFORMATION. Until such time as the Purchasers hold
collectively less than 10% of the outstanding voting stock of Celtrix, Celtrix
shall deliver to the Purchasers' designated representative, BioAsia Investments,
LLC (Xxxxx Xxxx, General Partner) (the "Purchasers' Representative" or
"BioAsia") within thirty (30) days after the end of each month, (a) a balance
sheet of Celtrix as of the end of such month and (b) a statement of income of
the Company as of the end of such month. All such financial statements to be
delivered under this Section shall be in accordance with the books and records
of Celtrix and shall have been prepared in accordance with generally accepted
accounting principles, except that such monthly financial statements may be
subject to normally recurring year-end adjustments and may delete any notes.
6.4 BUDGET. Attached hereto as Exhibit D is a copy of Celtrix's
Operating Plan for its current fiscal year as previously provided to Purchaser,
including its budget for the year. Celtrix agrees that it will not materially
deviate from the terms outlined in such Operating Plan unless approved by
unanimous consent of its Board of Directors. Furthermore, Celtrix shall afford
Purchasers' Representative the opportunity to discuss its views on such proposed
deviation with the Celtrix Board of Directors prior to implementing the proposed
deviation. Additionally, before the end of each fiscal year of Celtrix, Celtrix
shall deliver to Purchasers' Representative a
-16-
21
budget for such fiscal year, including projected balance sheets and statements
of income of Celtrix for each quarter of such fiscal year.
6.5 ACCESS. Celtrix shall allow Purchasers' Representative, upon
reasonable prior notice and during regular business hours no more than once per
quarter (a) full and free access to all books, records and properties of
Celtrix, for any reasonable purpose relating to Purchasers investment in Celtrix
and (b) the opportunity to interview the directors, officers and key employees
of Celtrix regarding the affairs of Celtrix.
6.6 BOARD OF DIRECTORS. Celtrix shall deliver to Purchasers'
Representative prior written notice of all meetings of the Board of Directors at
the same time such notices are distributed to the Directors and a copy of the
package distributed to the Directors in connection with the meeting. Purchasers
may designate a single representative to attend meetings of Celtrix's Board of
Directors as a non-voting observer.
6.7 PROCEEDINGS. Promptly after obtaining knowledge thereof, Celtrix
shall notify each Purchaser of (a) the commencement of any material action,
suit, claim, investigation or other proceeding by or before any court,
governmental authority or arbitrator against Celtrix, (b) any material judgment,
decree, injunction, or order of any court, governmental authority or arbitrator
entered against, or any settlement agreement entered into by, Celtrix.
6.8 INSURANCE. Celtrix shall maintain such insurance with coverage and
in amounts as shall be customary for Celtrix's industry and reasonable in light
of the Celtrix's financial condition and stage of business development,
including without limitation liability and extended coverage insurance and
workers' compensation insurance.
6.9 PROPRIETARY INFORMATION AGREEMENTS. All employees and consultants of
Celtrix who have access to confidential information as part of their employment
or engagement have already executed or shall be required to execute and deliver
a Proprietary Information Agreement in such form as may be approved by the Board
of Directors of the Company.
6.10 TAXES AND OTHER LIABILITIES. Celtrix shall make reasonable efforts
to pay and discharge, before the same become delinquent and before penalties
accrue thereon (all subject to the disclosures concerning taxes contained
elsewhere in this Agreement), all taxes, assessments and governmental charges
upon or against it or any of its properties, and all its other material
liabilities at any time existing, except to the extent and so long as (a) the
same are being contested in good faith and by appropriate proceedings in such
manner as not to cause any materially adverse effect upon the financial
condition of Celtrix or the loss of any right of redemption from any sale
thereunder; and (b) Celtrix shall have set aside on its books adequate reserves
(segregated to the extent required by generally accepted accounting principles)
with respect thereto, all subject to decisions of the Board of Directors
otherwise and/or to the financial condition of Celtrix and the business judgment
of management at the relevant point in time.
6.11 CORPORATE EXISTENCE. Celtrix shall use best efforts to maintain its
corporate existence, assets and foreign qualifications in all necessary
jurisdictions at all necessary points in time.
-17-
22
6.12 BUSINESS. Celtrix shall not change its current line of business, or
enter into any line of business other than its current line of business, or make
any material change in its current line of business, except as shall be approved
by its Board of Directors. Furthermore, Celtrix shall afford Purchaser's
Representative the opportunity to discuss its views on such proposed change with
the Celtrix Board of Directors prior to implementing the proposed change.
6.13 COMPLIANCE WITH LAWS. Celtrix shall comply with all material laws
and regulations applicable to it in all material respects.
6.14 INDEMNIFICATION.
(a) Celtrix shall indemnify and hold Purchasers and their
respective partners, stockholders, directors, officers and employees
(collectively, the "Indemnified Parties") harmless from and against, and agree
to promptly defend each of the Indemnified Parties from and reimburse each of
the Indemnified Parties for, any and all losses, damages, costs, expenses,
liabilities, obligations and claims of any kind (including, without limitation,
reasonable attorney fees (collectively, a "Loss") that any of the Indemnified
Parties may at any time suffer or incur, or become subject to, as a result or in
connection with:
(i) any breach or inaccuracy of any representations and
warranties made by Celtrix in this Agreement, or in any certificate or affidavit
delivered by Celtrix at the Closing in accordance with the provisions hereof;
(ii) any failure by Celtrix to fulfill its obligations
hereunder or under the Warrant; and
(iii) any suit, action or other proceeding arising out
of, or in any way related to, any of the matters referred to in this Section
6.14.
(b) An Indemnified Party shall notify Celtrix in writing of any
claim or demand (a "Claim") that the Indemnified Party has determined has given
or could give rise to a right of indemnification under this Agreement. Subject
to Celtrix's right to defend in good faith third party claims as hereinafter
provided, Celtrix shall satisfy its obligations under this Section 6.14 within
60 days after the receipt of written notice thereof from the Indemnified Party.
(c) If the Indemnified Party shall notify Celtrix of any Claim
pursuant to Section 6.14(a) hereof, and if such Claim relates to a Claim
asserted by a third party against the Indemnified Party that Celtrix
acknowledges is a Claim for which it must indemnify or hold harmless the
Indemnified Party under Section 6.14(a), Celtrix shall have the right, at its
sole cost and expense, to employ counsel of its own choosing reasonably
satisfactory to the Indemnified Party to defend any such Claim asserted against
the Indemnified Party; provided, however, that if the Indemnified Party (i)
reasonably believes that its interests with respect to a Claim (or any material
portion thereof) are in conflict with the interests of Celtrix with respect to
such Claim (or portion thereof), and (ii) promptly notifies Celtrix, in writing,
of the nature of such conflict, then, subject to the provisions of the following
sentence, the Indemnified Party shall be entitled to choose, at the sole cost
and expense of Celtrix, independent counsel to defend such Claim. In
-18-
23
the event that Celtrix does not agree that the Indemnified Party's interests
with respect to any such Claim are in conflict with the interests of Celtrix,
Celtrix shall so notify the Indemnified Party and the parties agree that they
shall each appoint a representative to meet within ten (10) business days after
Celtrix's notification to the Indemnified Party and such representatives will
discuss the issue and diligently work to resolve their differing views. The
Indemnified Party shall have the right to participate in the defense of any such
Claim at its own expense (except to the extent provided in the foregoing
sentence), but Celtrix shall retain control over such litigation (except as
provided in the foregoing sentence). Celtrix shall notify the Indemnified Party
in writing, as promptly as possible (but in any case before the due date for the
answer or response to a claim) after the date of the notice of claim given by
the Indemnified Party to Celtrix under section 6.14(b) hereof of its election to
defend in good faith any such third party Claim. So long as Celtrix is defending
in good faith any such Claim asserted by a third party against the Indemnified
Party, the Indemnified Party shall not settle or compromise such Claim without
the prior written consent of Celtrix. The Indemnified Party shall cooperate with
Celtrix in connection with any such defense and shall make available to Celtrix
or its agents all records and other materials in the Indemnified Party's
possession reasonably required by it for its use in contesting any third party
Claim; provided, however, that Celtrix shall have agreed, in writing, to keep
such records and other materials confidential except to the extent required for
defense of the relevant Claim. Whether or not Celtrix elects to defend any such
Claim, the Indemnified Party shall have no obligation to do so.
6.15 MATERIAL EVENTS. If the Purchasers' Representative is absent from
any meeting of the Board of Directors at which any of the following events is
announced, discussed or approved, Celtrix shall promptly notify Purchaser's
Representative of the same: (a) the execution of any material agreement to which
Celtrix is a party, (b) the termination of any material agreement to which
Celtrix is a party, (c) the resignation, termination or hiring of any key
employee or any material restructuring of Celtrix's labor force, (d) any
material labor dispute, (e) any material developments related to Celtrix's
intellectual property, (f) the occurrence of any other event that would have a
material effect upon Celtrix and/or its business, operations, prospects or
financial condition, and (g) any issuance of Celtrix Common Stock, Preferred
Stock, securities convertible into Celtrix Common Stock or Preferred Stock, or
the granting of any rights to acquire the same.
6.16 STOCKHOLDER RATIFICATION. Celtrix agrees that in connection with
its next annual meeting of stockholders (or in connection with any special
meeting of stockholders that may occur prior to such annual meeting date), it
shall solicit stockholder ratification of this Agreement and of the transactions
contemplated hereunder.
SECTION 7
COVENANTS OF PURCHASERS
7.1 NOTICE TO COMPANY OF PROPOSED SALE AND RIGHT OF COMPANY TO SUSPEND
USE OF REGISTRATION STATEMENT. If any Purchaser (as defined in Section 6.2
above) shall propose to sell any Registrable Securities pursuant to the
Registration Statement, it shall notify Celtrix of its intent to do so at least
three (3) full trading days prior to such sale, and the provision of such
-19-
24
notice to Celtrix shall conclusively be deemed to establish an agreement by such
Purchaser to comply with the registration provisions herein described. Unless
otherwise specified in such notice, such notice shall be deemed to constitute a
representation that any information previously supplied by such Purchaser is
accurate as of the date of such notice. At any time within such three (3)
trading-day period, Celtrix may refuse to permit the Purchaser to resell any
Registrable Securities pursuant to the Registration Statement; provided,
however, that in order to exercise this right, Celtrix must deliver a
certificate in writing to the Purchaser to the effect that a delay in such sale
is necessary because a sale pursuant to such Registration Statement in its
then-current form could constitute a violation of the federal securities laws.
In no event shall such delay exceed ten (10) trading days; provided, however,
that if, prior to the expiration of such ten (10) trading day period, Celtrix
delivers a certificate in writing to the Purchaser to the effect that a further
delay in such sale beyond such ten (10) trading day period is necessary because
the disclosures required to be made for a sale pursuant to such Registration
Statement to be in compliance with federal securities laws would be seriously
detrimental to Celtrix and its stockholders, Celtrix may refuse to permit such
Purchaser to resell any Registrable Securities pursuant to the registration
statement for an additional period not to exceed ten (10) trading days. Celtrix
may not utilize this right more than once in any three (3) month period.
7.2 RESTRICTIONS ON SHORT-SALES. No Purchaser shall engage in any
short-sales of Celtrix's Common Stock prior to the effectiveness of the
Registration Statement, except to the extent that any such short-sale is fully
covered by freely tradable shares of Common Stock of Celtrix.
SECTION 8
RESTRICTIONS ON TRANSFERABILITY OF SHARES; COMPLIANCE WITH SECURITIES ACT
8.1 RESTRICTIONS ON TRANSFERABILITY. The Shares, Warrants and Warrant
Shares shall not be transferable in the absence of a registration under the
Securities Act or an exemption therefrom or in the absence of compliance with
any term of this Agreement. Celtrix shall be entitled to give stop transfer
instructions to the transfer agent with respect to the Shares in order to
enforce the foregoing restrictions.
8.2 RESTRICTIVE LEGEND. Each certificate representing Shares, Warrants
and Warrant Shares shall bear substantially the following legends (in addition
to any legends required under applicable securities laws):
THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT
AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF REGISTRATION UNDER THE
SECURITIES ACT OF 1933 OR AN EXEMPTION THEREFROM.
UNTIL __________, 2000 THE SHARES REPRESENTED BY THIS CERTIFICATE MAY NOT BE
SOLD OR TRANSFERRED UNLESS PRIOR NOTICE SHALL HAVE BEEN GIVEN TO CELTRIX.
-20-
25
The legend contained in this Section 8.2 will be removed from a
certificate if (i) Celtrix receives an opinion of counsel reasonably
satisfactory to Celtrix that the Shares or Warrant Shares represented by such
certificates are available for resale pursuant to Rule 144 under the Securities
Act, or (ii) in Celtrix's opinion the Shares or Warrant Shares represented by
such certificates are available for resale pursuant to Rule 144(k) under the
Securities Act, or (iii) such Shares or Warrant Shares are sold pursuant to an
effective registration statement with the SEC.
SECTION 9
MISCELLANEOUS
9.1 TERMINATION OF AGREEMENT.
(a) This Agreement may be terminated at any time prior to the
Effective Time by Celtrix or any Purchaser if there has been a material breach
of any representation, warranty, covenant or agreement on the part of the other
party set forth in this agreement, which breach shall not have been cured, in
the case of a representation or warranty, prior to the Closing or, in the case
of a covenant or agreement, within thirty (30) calendar days following receipt
by the breaching party of written notice of such breach from the other party.
(b) From and after the termination of this Agreement, the
covenants, obligations and agreements of the parties set forth herein shall be
of no further force or effect and the parties shall be under no further
obligation with respect thereto.
9.2 BEST EFFORTS. Celtrix and each Purchaser shall use its best efforts
to take all actions required under any law, rule or regulation adopted
subsequent to the date hereof in order that Celtrix may sell the Units to
Purchasers and Purchasers may purchase the Units, and to ensure that the
conditions to a Closing set forth herein are satisfied on or before the
scheduled date of such Closing.
9.3 GOVERNING LAW. This Agreement shall be governed in all respects by
the laws of the State of California as applied to contracts entered into solely
between residents of, and to be performed entirely within, such state.
9.4 SURVIVAL. The representations and warranties, in Sections 2 and 3 of
this Agreement shall survive any investigation made by any Purchaser or Celtrix
and the Closing; provided that such representations and warranties shall not be
construed so as to constitute representations and warranties concerning
circumstances existing after the date of this Agreement.
9.5 SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and
shall inure to the benefit of the parties hereto and their respective successors
and assigns. This Agreement may not be assigned by a party without the prior
written consent of the other party.
9.6 ENTIRE AGREEMENT; AMENDMENT. This Agreement, the Warrants and the
other documents delivered pursuant hereto constitute the full and entire
understanding and agreement
-21-
26
between the parties with regard to the subject matter hereof and thereof and
supersedes all prior agreements and understandings among the parties relating to
the subject matter hereof. With the exception of Section 6 hereof, the terms of
this Agreement may be waived or amended with the written consent of Celtrix and
each Purchaser. With respect to Section 6 hereof, with the written consent of
Celtrix and the record holders of more than fifty percent (50%) of the
Registrable Securities then outstanding the terms of this Agreement may be
waived and amended and any such amendment or waiver shall be binding upon
Celtrix and all holders of Shares.
9.7 NOTICES AND DATES. Any notice or other communication given under
this Agreement shall be sufficient if in writing and sent by registered or
certified mail, domestic or international courier, or facsimile, return receipt
requested, postage or courier charges prepaid, to a party at its address set
forth below (or at such other address as shall be designated for such purpose by
such party in a written notice to the other party hereto):
(a) if to Celtrix, to:
Celtrix Pharmaceuticals, Inc.
0000 Xxxxxxx Xxxxx Xxxxx
Xxxxx Xxxxx, XX 00000-0000
Attention: Chief Financial Officer
with a copy to:
Xxxxxx X. Xxxxxx, Xx.
Venture Law Group
0000 Xxxx Xxxx Xxxx
Xxxxx Xxxx, XX 00000
(b) if to Purchasers, to the respective address set forth
on the attached Schedule of Purchasers
with a copy to:
Xxx X. Xxxxxxxxx
Nordlicht & Hand
Olympic Tower
000 Xxxxx Xxxxxx
Xxx Xxxx, XX 00000
All such notices and communications shall be effective one (1)
trading day after being sent by courier or by facsimile with confirmation of
receipt or five (5) trading days after being sent by the other approved methods.
-22-
27
9.8 SEVERABILITY. If any term, provision, covenant or restriction of
this Agreement is held by a court of competent jurisdiction to be invalid, void
or unenforceable, the remainder of the terms, provisions, covenants and
restriction of this Agreement shall remain in full force and effect and shall in
no way be affected, impaired or invalidated.
9.9 NO THIRD PARTY RIGHTS. Nothing in this Agreement shall create or be
deemed to create any rights in any person or entity not a party to this
Agreement.
9.10 COUNTERPARTS. This Agreement may be executed in counterparts, and
each such counterpart shall be deemed an original for all purposes, but such
counterparts shall together constitute one and the same instrument.
9.11 EXPENSES. Celtrix and each Purchaser shall bear its own expenses
incurred on its behalf with respect to this Agreement and the transactions
contemplated hereby, except that if the Closing occurs, the Company shall
reimburse the Purchasers for documented, itemized and reasonable fees and
expenses incurred by them not to exceed $50,000 in the aggregate.
[SIGNATURE PAGE FOLLOWS]
-23-
28
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their respective authorized officers as of the date first above
mentioned.
CELTRIX PHARMACEUTICALS, INC.
By: /s/ Xxxxxxx Xxxxxx
-----------------------------
Title: President & CEO
-----------------------------
PURCHASERS
Name: /s/ Xxxxx Xxxx
-----------------------------
By: Xxxxx Xxxx
-----------------------------
Title: General Partner
-----------------------------
Biotechnology Development
Fund, L.P.
-----------------------------
Name: /s/ Xxxxx Xxxx
-----------------------------
By: Xxxxx Xxxx
-----------------------------
Title: General Partner
-----------------------------
Biotechnology Development
Fund, III L.P.
-----------------------------
Name: /s/ Xxxxxx X X Xxxxx
-----------------------------
By: For and on behalf of Veron
International Limited
(Incorporated in BVI)
-----------------------------
Title: Director
-----------------------------
Name: XXX XXX XXXX
-----------------------------
By: /s/ Wei-Xxxx Xxx
-----------------------------
Title:
-----------------------------
Name: For and on behalf of
Lion International Management
Limited as sole Director of
Hofung Holdings Limited
-----------------------------
By: /s/ [R] Xxxxxxx
-----------------------------
Title: Authorized Signatory
-----------------------------
Name: /s/ Xxxxx Xxxx
-----------------------------
/s/ Wanpyag Chuang
-----------------------------
By: Xxxxx Xxxx & Wanpyag Chuang
-----------------------------
Title:
-----------------------------
29
Name: /s/ [J] Xxxxx
-----------------------------
By: Nai-xxxx Xxxxx
-----------------------------
Title:
-----------------------------
Name: XXX-XXXX YUAN
-----------------------------
By: /s/ Xxx-Xxxx Yuan
-----------------------------
Title:
-----------------------------
30
EXHIBIT A
SCHEDULE OF PURCHASERS
# SHARES # WARRANT
PURCHASER COMMON STOCK SHARES PURCHASE PRICE
--------- ------------ ----------- --------------
Biotechnology Development Fund, L.P. 500,000 750,000 $250,000
Xxxxx Xxxx, General Partner
000 Xxxx Xxxxxx
Xxxxx 000
Xxxx Xxxx, XX 00000
Biotechnology Development Fund, III 1,000,000 1,500,000 $500,000
L.P.
Xxxxx Xxxx, General Partner
000 Xxxxx Xxxxxx
Xxxxx 000
Xxxx Xxxx, XX 00000
Veron International, Ltd. 940,000 1,410,000 $470,000
Chinachem Xxxxxx Xxxxx
00 Xxxx Xxxx
Tsin Sha Tsui East
Kowloon, Hong Kong
Attn: X.X. Xxxxx
Xxx Xxx Xxxx 940,000 1,410,000 $470,000
c/o Fu Sheng Industrial Co., Ltd.
172 Nanking East Road, Sec. 2
Taipei 104, Taiwan
R.O.C.
Attn: Shubbin King
Hofung Holdings Limited. 380,000 570,000 $190,000
00 X Xxxx Xxxx Xxxx.
00 Xxxxxxx Xx.
Xxxxxxx, Xxxx Xxxx
Attn: Xxxxxx Xx
Wanpyng Chuang and Xxxxx Xxxx 100,000 150,000 $50,000
0000 Xxxxxx Xxxxx Xx.
Xxxxxxxx, XX 00000
Nai-Xxxx Xxxxx 60,000 90,000 $30,000
00X, Xxxx Xxxx 0/X
Xxxxxxx Xxxxxxxx
Xxxx Xxxx
31
Xxx-Xxxx Yuan 80,000 120,000 $40,000
8/F 33 One hundred fifty first Xxxxxx
Xxxxxx Xxxxxxxx
Xxx-xx Xxxxxx
Xxxxxx, X.X.X.
----------- ----------- ----------
Total 4,000,000 6,000,000 $2,000,000
